Arbutus Biopharma Corp: Form 10-Q for the period ended Jun 30, 2020
Filed with the SEC on Aug 7, 2020 and accepted by EDGAR at Aug 7, 2020, 16:24 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2020-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2020-04-01 to 2020-06-30 | $1.5m | us-gaap:Revenues |
| Revenue | 6 months2020-01-01 to 2020-06-30 | $3.0m | us-gaap:Revenues |
| Research and development | 3 months2020-04-01 to 2020-06-30 | $10.5m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2020-01-01 to 2020-06-30 | $20.9m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2020-04-01 to 2020-06-30 | −$13.1m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2020-01-01 to 2020-06-30 | −$26.3m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2020-04-01 to 2020-06-30 | $1.1m | us-gaap:InterestExpense |
| Interest expense | 6 months2020-01-01 to 2020-06-30 | $2.1m | us-gaap:InterestExpense |
| Income tax | 3 months2020-04-01 to 2020-06-30 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months2020-01-01 to 2020-06-30 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2020-04-01 to 2020-06-30 | −$14.1m | us-gaap:NetIncomeLoss |
| Net income | 6 months2020-01-01 to 2020-06-30 | −$27.9m | us-gaap:NetIncomeLoss |
| Operating cash flow | 6 months2020-01-01 to 2020-06-30 | −$24.3m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2020-01-01 to 2020-06-30 | $66.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2020-06-30 | $45.9m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2020-06-30 | $85.5m | us-gaap:AssetsCurrent |
| Total assets | At period end2020-06-30 | $97.6m | us-gaap:Assets |
| Current liabilities | At period end2020-06-30 | $6.3m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2020-06-30 | $32.1m | us-gaap:Liabilities |
| Shareholders' equity | At period end2020-06-30 | $65.5m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001447028-20-000118. Last ingested by Listed: Nov 12, 2026, 17:55 ET. Listed shows no prices and gives no investment advice.